FOLH1 and posterior cortical atrophy: Thus, there is an urgent need for an adequately powered, non-inferiority RCT of ePLND vs. no PLND in men undergoing RP for high risk Pca, combining a long-term PCa-survival primary endpoint with secondary oncologic, morbidity, QOL and cost endpoints, and ideally incorporating pre-operative PSMA-PET/CT (to guide ePLND beyond the template if positive, but not to guide selection for ePLND).